C4X Discovery Holdings PLC Exercise of Options (0360A)
May 27 2021 - 4:04AM
UK Regulatory
TIDMC4XD
RNS Number : 0360A
C4X Discovery Holdings PLC
27 May 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Exercise of options
Issue of equity
27 May 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces it has issued 80,625
ordinary shares of 1p each in the Company ("New Ordinary Shares")
following the exercise of options by an employee of the
Company.
Application has been made for the New Ordinary Shares to be
admitted to trading on AIM and dealings are expected to commence on
or around 8.00 a.m. on 2 June 2021.
The New Ordinary Shares rank pari passu with the existing shares
of the Company. Following the issue of the New Ordinary Shares, the
Company's issued share capital now consists of 226,426,627 ordinary
shares. Accordingly, the figure of 226,426,627 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
neurodegeneration, oncology and addictive disorders . Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For more information visit
us at www.c4xdiscovery.com or follow us on twitter
@C4XDiscovery.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEDKOBKCBKKNPB
(END) Dow Jones Newswires
May 27, 2021 05:04 ET (09:04 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Mar 2024 to Apr 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2023 to Apr 2024